501.382.1234
205 McAuley Ct Hot Springs, AR 71913
Scientific Research
Appointment

In the Media

Press & Recognition
Featured Coverage
Ben's pioneering approach to opioid-free chronic pain care has earned national recognition from the country's leading healthcare and nursing organisations.
AANA
American Association of
Nurse Anesthesiology
November 19, 2025
National Feature

CRNA Brings Hope and Healing to Rural Patients Facing Chronic Pain

The American Association of Nurse Anesthesiology (AANA) profiles Ben Campbell's mission to bring opioid-free, regenerative pain care to rural Arkansas — and how his work is inspiring CRNAs nationwide to expand into chronic pain management. Patients travel from as far as Arizona, Maryland, and Wisconsin to receive his care in Hot Springs, Arkansas.

Read Full Article →
USF
Health
University of
South Florida
July 31, 2025
Alumni Feature

Staying on the Cutting Edge Through Advanced Pain Management Fellowship

The University of South Florida College of Nursing features Ben Campbell's journey through the USF Advanced Pain Management Fellowship — from treating soldiers in combat to opening his own chronic pain clinic in rural Arkansas. Now serving as Clinical Coordinator for the fellowship, Ben is shaping the next generation of CRNAs in transformative pain care.

Read Full Article →

Regenerative Pain Solutions specializes in innovative restorative therapies to treat chronic pain at its source. Focusing on promoting the body to repair itself rather than masking symptoms, the clinic provides long-term relief and enhances patients’ overall well-being. 

Common Conditions

Schedule Your Appointment

Click the button below to book your appointment with our medical team.
Your health is our priority.

Book an Appointment

Copyright © 2024 Regenerative Pain Solutions

Terms & Conditions | Privacy Policy

Discover the science behind our success!

Regenerative Pain Solutions proudly uses Ggevityy products.

Click here to learn more about the groundbreaking scientific research

Book An Appointment

To learn more about our restorative therapies and whether or not you are a candidate, please fill the calendar below to book an appointment. We believe in personalized care because each individual is unique.

Terms & Conditions | Pivacy Policy

Mesenchymal stem cells (MSCs) are undifferentiated cells with a high proliferation capacity and mesodermal differentiation potential [1]. They are an important source of stem cells for damaged tissue regeneration in clinical applications. Although bone marrow (BM) has conventionally been used as the major source of pluripotent MSCs, BM collection requires a highly invasive procedure. Furthermore, with increasing age, the number, differentiation potential, and lifespan of MSCs from BM decrease [2]. Therefore, the umbilical cord and adipose tissue (AD) are used as alternative sources of MSCs [2]. Umbilical cord-derived stem cells originating in Wharton’s jelly (WJ) are called Wharton’s jelly mesenchymal stem cells (WJ-MSCs). They form a class of stem cells with a high differentiation potential, an immuno-privileged status, and easy access for collection, raising no legal or ethical issues. WJ-MSCs exhibit several features of embryonic stem cells, such as a short doubling time and potent expansion capacity, with only a few differences [3].

Read the full article
Mesenchymal stem cells (MSCs) are undifferentiated cells with a high proliferation capacity and mesodermal differentiation potential [1]. They are an important source of stem cells for damaged tissue regeneration in clinical applications. Although bone marrow (BM) has conventionally been used as the major source of pluripotent MSCs, BM collection requires a highly invasive procedure. Furthermore, with increasing age, the number, differentiation potential, and lifespan of MSCs from BM decrease [2]. Therefore, the umbilical cord and adipose tissue (AD) are used as alternative sources of MSCs [2]. Umbilical cord-derived stem cells originating in Wharton’s jelly (WJ) are called Wharton’s jelly mesenchymal stem cells (WJ-MSCs). They form a class of stem cells with a high differentiation potential, an immuno-privileged status, and easy access for collection, raising no legal or ethical issues. WJ-MSCs exhibit several features of embryonic stem cells, such as a short doubling time and potent expansion capacity, with only a few differences [3].
Read the full article
MSCs reside primarily in the bone marrow, where they were first characterized; nevertheless, they have a broad post-natal organ distribution (Friedenstein et al., 1970). MSCs have been isolated from different adult and fetal tissues (Uder et al., 2018). The adult tissues include adipose tissue, skeletal muscle, bone marrow, molar teeth/dental pulp, synovium/synovial fluid, skin, hematopoietic supportive stroma, and others (da Silva Meirelles et al., 2006). The fetal tissues include peripheral and umbilical cord blood, umbilical cord stroma or tissue, placenta, amniotic fluid, endometrium (da Silva Meirelles et al., 2006; Jiang et al., 2011). Although, MSCs share common characteristics including the expression of common cell surface markers (CD105, CD73 and CD90) and multipotency capacity to differentiate into osteoblasts, chondrocytes, or adipocytes (Carvalho et al., 2011; Ghaneialvar et al., 2018), they have different expression profiles and properties.
Read the full article
There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However, limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application procedures (local and direct). The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157, as a feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle healing. Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further, over the past two decades, only a handful of research groups have performed in-depth studies regarding this peptide. Despite this, it is apparent that BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover, skeletal muscle injury models have suggested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical realisation.
Read the full article

Book An Appointment


Book An Appointment

To learn more about our restorative therapies and whether or not you are a candidate, please fill the calendar below to book an appointment. We believe in personalized care because each individual is unique.

Terms & Conditions | Pivacy Policy

About Us

Ben Campbell: A Journey to Pioneering Regenerative Pain Solutions

For decades, Ben Campbell dedicated his career to enhancing patient comfort and effective pain management. His journey began in the late 1980s as a nurse anesthesiologist, where he tirelessly sought to improve pain relief techniques post-anesthesia. He explored regional anesthetics, spinals, epidurals, and individual nerve blocks, constantly refining his methods to ensure patients woke up pain-free and comfortable.

In his early days, Campbell was among the pioneers introducing epidural infusions for labor, providing consistent pain relief throughout labor rather than short-term single doses. He embraced ultrasound technology, teaching himself to use it for more precise nerve blocks, and shared knowledge with peers through courses and seminars. This innovation allowed him to perform anesthesia without relying on narcotics, leading to faster patient recovery and greater satisfaction.

Driven by a desire to prevent patients from needing surgery, he pursued a fellowship in chronic pain management. Transitioning from anesthesiology, he established a practice focused on comprehensive pain relief. However, he realized that traditional methods, such as steroid injections and nerve burning, provided only temporary relief and potentially harmful long-term effects.

Frustrated by the limitations of conventional treatments, Campbell explored restorative medicine as a path to lasting healing. This shift was inspired by a profound insight: rather than masking pain or using destructive techniques, why not promote healing at the source? Through extensive research, training, and practical application, he began incorporating restorative therapies into his practice, eventually dedicating himself entirely to this innovative approach.

Today, at Regenerative Pain Solutions, Ben Campbell is committed to treating the underlying causes of pain, helping patients achieve long-term wellness. Although insurance coverage for restorative treatments is limited, he strives to make these therapies accessible, often providing discounts to ensure more patients can benefit. Campbell’s journey from traditional pain management to restorative medicine embodies his unwavering dedication to improving patient care and outcomes.

Learn More
Call Now Button